This publication summarises data from PRIMA, a phase 3 randomised controlled trial of niraparib for the treatment of advanced ovarian cancer in the first-line setting. Final overall survival results from PRIMA are now available, after a median 6.2 years of follow-up.
Please login below to download this issue (PDF)